No Prescription |
 |
 | ||
|
CIPLAR LA Inderal |
|
| ||
No Prescription » Prescription Drugs 4 » CIPLAR LA Inderal Propranolol is a beta blocker. It works by slowing down the heart and decreasing the amount of blood it pumps out. This helps to decrease blood pressure helps the heart pump more efficiently and reduces the workload on the heart.HypertensionPropranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents particularly a thiazide diuretic. Propranolol is not indicated in the management of hypertensive emergencies. HypertensionPropranolol LA is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents particularly a thiazide diuretic. Inderal LA is not indicated in the management of hypertensive emergencies.Angina Pectoris Due to Coronary AtherosclerosisPropranolol LA is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris.MigrainePropranolol LA is indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established and propranolol is not indicated for such use.Hypertrophic Subaortic StenosisPropranolol LA improves NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Buy CIPLAR LA Inderal and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About CIPLAR LA Inderal: Product Type: Prescription Drugs 4 CIPLAR-LA ( Inderal Generic Propranolol ) CIPLAR-LA (Inderal Generic Propranolol) Inderal Generic Propranolol 80mg tabs 100 (10 x 10) 40mg 10 x 10 Tablets Inderal Generic Propranolol CIPLAR-LA
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
